Overview

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The objectives of this study are: - To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) - To evaluate efficacy of Nyxol to improve visual performance - To evaluate the safety of Nyxol
Phase:
Phase 3
Details
Lead Sponsor:
Ocuphire Pharma, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Phentolamine